Ask AI
ProCE Banner Series

In ESR1-mutated, ER+/HER2- mBC following progression on ET, ORSERDU (elacestrant): The 2nd Line Standard of Care for ESR1m

  1. ESR1 mutations as a driver of progression in ER+/HER2- mBC
  2. Benefit of liquid biopsies to detect acquired ESR1 mutations
  3. ORSERDU efficacy and safety data to optimize patient management

Key Takeaways:

  • The proven combination of efficacy and safety for your patients with ESR1m2
  • Primary Endpoint 2x PFS
  • 8.6 months mPFS Exploratory Post Hoc Analysis
  • Demonstrated Safety Profile: Most Common AEs were grade 1 or 1.

All Events

In ESR1-mutated, ER+/HER2- mBC following progression on ET, ORSERDU (elacestrant): The 2nd Line Standard of Care for ESR1m

Upcoming Events

October

30

2025

3:15 PM - 4:00 PM Eastern Time (ET)

Virtual

November

06

2025

12:15 PM - 1:00 PM Eastern Time (ET)

Virtual

Additional Info

Acknowledgement

Sponsored By

Stemline

Stemline